Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Novo Nordisk A/S, Novo Allé, DK-2880, Bagsværd, Denmark
NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection.
NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection.
NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection.
NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection.
Pharmaceutical Form |
---|
Powder and solvent for solution for injection. White lyophilised powder. Solvent: clear colourless solution. The reconstituted solution has a pH of approximately 6.0. |
NovoSeven 1 mg (50 KIU): NovoSeven is presented as powder and solvent for solution for injection containing 1 mg eptacog alfa (activated) per vial (corresponds to 50 KIU/vial).
NovoSeven 2 mg (100 KIU): NovoSeven is presented as powder and solvent for solution for injection containing 2 mg eptacog alfa (activated) per vial (corresponds to 100 KIU/vial).
NovoSeven 5 mg (250 KIU): NovoSeven is presented as powder and solvent for solution for injection containing 5 mg eptacog alfa (activated) per vial (corresponds to 250 KIU/vial).
NovoSeven 8 mg (400 KIU): NovoSeven is presented as powder and solvent for solution for injection containing 8 mg eptacog alfa (activated) per vial (corresponds to 400 KIU/vial).
1 KIU equals 1,000 IU (International Units).
Eptacog alfa (activated) is recombinant coagulation factor VIIa (rFVIIa) with a molecular mass of approximately 50,000 Daltons produced in baby hamster kidney cells (BHK Cells) by recombinant DNA technology.
After reconstitution, the product contains 1 mg/ml eptacog alfa (activated) when reconstituted with solvent.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Coagulation factor VIIa |
Pharmacological doses of rFVIIa activate factor X directly on the surface of activated platelets, localized to the site of injury, independently of tissue factor. This results in the conversion of prothrombin into large amounts of thrombin independently of tissue factor. |
List of Excipients |
---|
Powder: Sodium chloride Solvent: Histidine |
The solvent of NovoSeven is provided in either a vial or in a pre-filled syringe. Not all presentations may be marketed.
The NovoSeven 1 mg (50 KIU)/NovoSeven 2 mg (100 KIU) package contains either:
or
The NovoSeven 5 mg (250 KIU)/NovoSeven 8 mg (400 KIU) package contains either:
or
Vial: Type I glass vial closed with a chlorobutyl rubber stopper, covered with an aluminium cap. The closed vial is equipped with a polypropylene tamper-evident snap-off cap.
Pre-filled syringe: Type I glass barrel with a polypropylene backstop and bromobutyl rubber plunger. The syringe cap consists of bromobutyl rubber and polypropylene tamper evident seal.
Plunger rod: made of polypropylene.
Novo Nordisk A/S, Novo Allé, DK-2880, Bagsværd, Denmark
NovoSeven 1 mg (50 KIU):
EU/1/96/006/004
EU/1/96/006/008
NovoSeven 2 mg (100 KIU):
EU/1/96/006/005
EU/1/96/006/009
NovoSeven 5 mg (250 KIU):
EU/1/96/006/006
EU/1/96/006/010
NovoSeven 8 mg (400 KIU):
EU/1/96/006/007
EU/1/96/006/011
Date of first authorisation: 23 February 1996
Date of latest renewal: 23 February 2006
Drug | Countries | |
---|---|---|
NOVOSEVEN | Austria, Brazil, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.